Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bovie Medical Co. stock logo
BVX
Bovie Medical
$6.48
+1.1%		$6.48
$2.28
▼
$7.70
$215.14MN/A136,878 shs129,500 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$5.77
-3.8%		$6.67
$2.80
▼
$8.97
$208.06M0.6337,931 shs1.36 million shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bovie Medical Co. stock logo
BVX
Bovie Medical
0.00%0.00%0.00%0.00%0.00%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-2.04%+0.87%+12.48%-34.06%-50.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bovie Medical Co. stock logo
BVX
Bovie Medical
$6.48
+1.1%		$6.48
$2.28
▼
$7.70
$215.14MN/A136,878 shs129,500 shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$5.77
-3.8%		$6.67
$2.80
▼
$8.97
$208.06M0.6337,931 shs1.36 million shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bovie Medical Co. stock logo
BVX
Bovie Medical
0.00%0.00%0.00%0.00%0.00%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-2.04%+0.87%+12.48%-34.06%-50.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bovie Medical Co. stock logo
BVX
Bovie Medical
0.00
N/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bovie Medical Co. stock logo
BVX
Bovie Medical
N/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bovie Medical Co. stock logo
BVX
Bovie Medical
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/AN/A-29.62%-28.20%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bovie Medical Co. stock logo
BVX
Bovie Medical
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bovie Medical Co. stock logo
BVX
Bovie Medical
N/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Institutional Ownership

CompanyInstitutional Ownership
Bovie Medical Co. stock logo
BVX
Bovie Medical
N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
Bovie Medical Co. stock logo
BVX
Bovie Medical
N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bovie Medical Co. stock logo
BVX
Bovie Medical
N/A33.20 millionN/ANot Optionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

Recent News About These Companies

Meet the Silverback, the Leader of the Troop
October 17, 2024  |  pbs.orgP
10 Fun Facts About Mountain Gorillas
September 18, 2024  |  nationalgeographic.comN
CapstanTx secures $165 million to deliver precise in vivo cell engineering
July 28, 2024  |  pharmaphorum.comP
ARS Pharmaceuticals Inc (SPRY)
May 11, 2023  |  uk.investing.comhttps://uk.investing.com/equities/silverback-therapeutics-inc
Wild Isles
March 12, 2023  |  wwf.org.ukW
A look back at RNA Therapeutics – day one
February 23, 2023  |  pharmaphorum.comP
SPRY ARS Pharmaceuticals, Inc.
January 24, 2023  |  seekingalpha.comhttps://seekingalpha.com/symbol/SPRY
ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger
November 22, 2022  |  247wallst.comhttps://247wallst.com/investing/2022/11/22/ars-pharma-ceo-richard-lowenthal-holds-8-silverback-stake-after-merger/
Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics
November 18, 2022  |  nasdaq.comhttps://www.nasdaq.com/articles/dr.-sarina-tanimoto-discloses-position-in-sbtx-silverback-therapeutics
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
November 10, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/ars-pharmaceuticals-announces-presentation-clinical-130000987.html?.tsrc=rss
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
November 8, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/ars-pharmaceuticals-closes-merger-silverback-210200048.html?.tsrc=rss
Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions
October 28, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/silverback-fda-accepts-ars-pharm-s-nda-for-neffy-for-treatment-of-allergic-reactions-1031824142
FDA accepts ARS Pharma’s NDA for Neffy
October 24, 2022  |  thepharmaletter.comT
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI
October 23, 2022  |  kentuckytoday.comK
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
October 21, 2022  |  finance.yahoo.comhttps://finance.yahoo.com/news/silverback-therapeutics-inc-announces-fda-113100379.html?.tsrc=rss
Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?
October 19, 2022  |  aaii.comA
SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN
October 12, 2022  |  bakersfield.comB
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
September 17, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/investigation-alert-halper-sadeh-llc-investigates-cvet-sbtx-irbt-1031746211
SBTX Silverback Therapeutics, Inc.
September 15, 2022  |  seekingalpha.comhttps://seekingalpha.com/symbol/SBTX/charting
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
September 6, 2022  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/shareholder-notice-halper-sadeh-llp-investigates-ftai-sbtx-cvet-gbt-1031726462

Media Sentiment Over Time

Bovie Medical stock logo

Bovie Medical NYSEAMERICAN:BVX

$6.48 +0.07 (+1.09%)
As of 12/31/2018

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$5.77 -0.23 (-3.83%)
As of 09/1/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas